Leadership

Leadership

Our team is composed of experts with an unparalleled knowledge of science, technology, and medicine. Their immense depth of experience is ideally suited to the quest to reduce the burden of infectious disease around the globe.

John C. Jacobs
John C. Jacobs
President and Chief Executive Officer
John J. Trizzino
John J. Trizzino
President,
Chief Operating Officer
Mark Casey
Mark Casey
Executive Vice President,
Chief Legal Officer
Rick Crowley
Rick Crowley
Executive Vice President,
Chief Operations Officer
Jim Kelly
Jim Kelly
Executive Vice President,
Chief Financial Officer and
Treasurer
Elaine O’Hara
Elaine O’Hara
Executive Vice President,
Chief Strategy Officer
Silvia Taylor
Silvia Taylor
Executive Vice President,
Chief Corporate Affairs and Advocacy Officer
Ian Watkins
Ian Watkins
Executive Vice President,
Chief Human Resources Officer
Troy Morgan, JD
Troy Morgan, JD
Senior Vice President,
Chief Compliance Officer
Robert Walker, MD
Robert Walker, MD
Senior Vice President,
Chief Medical Officer
(Interim Head of R&D)
John C. Jacobs
John C. Jacobs
President and Chief Executive Officer
James F. Young, PhD
James F. Young, PhD
Chairman of the
Board of Directors
Gregg Alton
Gregg Alton
Director
Richard Douglas, PhD
Richard Douglas, PhD
Director
Rachel King
Rachel King
Director
Margaret G. McGlynn, R. Ph.
Margaret G. McGlynn, R. Ph.
Director
David Mott
David Mott
Director
Rick Rodgers, MBA
Rick Rodgers, MBA
Director
Novavax’ Compliance program

Annual Declaration Clause for California (May 2024)

Novavax Inc. (Novavax) is committed to establishing and maintaining an effective compliance program that promotes conducting business activities in accordance with applicable laws, rules, and regulations, with the highest ethical standards in its interactions with all medical and health professionals and organizations. Novavax’ compliance program is designed to prevent, detect, and respond to potential instances of non-compliance. 

Novavax declares, in good faith as of May 24, 2024, that the company is in compliance with a Comprehensive Compliance Program and the requirements of the California Health & Safety Code §119400-119402. This declaration is based on Novavax’ review and understanding of the California Health & Safety Code §119400-119402 including the key components of a Comprehensive Compliance Program and the annual aggregate limit on promotional expenditures. Novavax will update this declaration on an annual basis. 

To obtain a written copy of our Code of Conduct or a written declaration of compliance, please contact 844-612-0252.

 

Careers

Build your future with us

Investors

Annual reports, events, and more

Science & Technology

Our pipeline—creating tomorrow's vaccine today